One would think that Syntax-Brillian would want to clear the books on Vivitar inorder to exepdite its sale, the only asset it has elected to spinoff. Any potential buyer would likely not find pending patent infringement litiagiton palatable, imo.

Settlement may be closer than we think...but you never know for certain.